Search results
Showing 3051 to 3100 of 4090 results for patient
In development Reference number: GID-TA11765 Expected publication date: TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]
In development Reference number: GID-TA11859 Expected publication date: TBC
Awaiting development Reference number: GID-TA11872 Expected publication date: TBC
Awaiting development Reference number: GID-TA11703 Expected publication date: 25 February 2026
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Awaiting development Reference number: GID-TA11065 Expected publication date: TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]
In development Reference number: GID-TA11818 Expected publication date: TBC
BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)
In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.
This guidance has been updated and replaced by NICE guideline NG107
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
In development Reference number: GID-TA11535 Expected publication date: TBC
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
In development Reference number: GID-TA11224 Expected publication date: TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
In development Reference number: GID-TA11759 Expected publication date: TBC
In development Reference number: GID-TA11657 Expected publication date: 07 April 2027
In development Reference number: GID-TA11590 Expected publication date: TBC
In development Reference number: GID-TA11813 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
In development Reference number: GID-TA11492 Expected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542
In development Reference number: GID-TA11525 Expected publication date: 10 February 2027
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development Reference number: GID-TA11036 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.
In development Reference number: GID-TA11812 Expected publication date: TBC
Awaiting development Reference number: GID-TA11878 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Awaiting development Reference number: GID-TA11100 Expected publication date: TBC
In development Reference number: GID-TA11869 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.
In development Reference number: GID-TA11776 Expected publication date: TBC
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]
Awaiting development Reference number: GID-TA11877 Expected publication date: TBC
Awaiting development Reference number: GID-TA11847 Expected publication date: TBC
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
In development Reference number: GID-TA11342 Expected publication date: TBC
In development Reference number: GID-TA11766 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
In development Reference number: GID-TA11499 Expected publication date: TBC
Awaiting development Reference number: GID-TA11281 Expected publication date: TBC
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
Awaiting development Reference number: GID-TA11606 Expected publication date: TBC
In development Reference number: GID-TA11592 Expected publication date: TBC
In development Reference number: GID-TA11625 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11687 Expected publication date: TBC
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for HTG129Show all sections
Sections for HTG129
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
In development Reference number: GID-TA11372 Expected publication date: TBC
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
In development Reference number: GID-TA11688 Expected publication date: TBC